Lexicon Pharmaceuticals, Inc. (LXRX) Stock
Fundamentals
Recent news

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
LXRX

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX

Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
LXRX

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
LXRX
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
LXRX

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
LXRX

Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
LXRX

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
LXRX

Here's Why You Should Add LXRX Stock to Your Portfolio Now
Here's Why You Should Add LXRX Stock to Your Portfolio Now
LXRX

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
LXRX

Lexicon Pharmaceuticals Q1 Earnings Call Highlights
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
LXRX

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
LXRX

5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
LXRX

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
LXRX
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael S. Exton Ph.D. | CEO & Director | 1970 |
| Mr. Scott M. Coiante | Senior VP & CFO | 1967 |
| Mr. Brian T. Crum | Senior VP, General Counsel & Secretary | 1973 |
| Ms. Wendy E. McDermott | Senior Vice President of Human Resources | 1971 |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior VP & Chief Medical Officer | 1965 |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting | 1968 |
| Ms. Lisa M. DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | 1980 |
| Dr. Suma Gopinathan M.S., Ph.D. | Senior Vice President of Discovery | 1973 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
0 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.0 | +9.8 | -19.4 | -14.0 | ||||||||
| 2022 | -18.5 | -36.9 | -0.9 | -19.6 | -8.3 | +6.3 | +22.7 | +16.0 | -13.0 | -12.2 | -3.6 | -10.7 |
| 2023 | +12.6 | -0.9 | +10.5 | -2.8 | +35.2 | -15.5 | -13.4 | -11.3 | -35.5 | +21.6 | -20.9 | +33.0 |
| 2024 | +17.6 | +25.8 | -3.2 | -32.5 | +3.0 | -4.0 | +17.9 | |||||
| 2026 | +36.3 | +15.9 | -1.3 | -3.4 | -17.8 |



